Organon boasted of a sub-33% dividend payout ratio.
Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Organon & Co. (NYSE:OGN ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matt Walsh - CFO Juan Camilo Arjona Ferreira - Head of R&D Conference Call Participants David Amsellem - Piper Sandler Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan Umer Raffat - Evercore ISI Bhavin Patel - Bank of America Operator Hello, and welcome to the Organon First Quarter 2025 Earnings Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Jennifer Halchak, Vice President, Investor Relations.
Organon (OGN) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $1.22 per share a year ago.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Organon (OGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
In the most recent trading session, Organon (OGN) closed at $12.20, indicating a +0.66% shift from the previous trading day.
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon (OGN) closed the most recent trading day at $11.30, moving +1.07% from the previous trading session.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.